soluble ferric pyrophosphate (SFP)
Pre-clinicalTerminated 0 views this week 0 watching💤 Quiet
Interest: 8/100
8
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End Stage Renal Disease (ESRD)
Conditions
End Stage Renal Disease (ESRD)
Trial Timeline
Jan 1, 2008 → Dec 1, 2010
NCT ID
NCT00604565About soluble ferric pyrophosphate (SFP)
soluble ferric pyrophosphate (SFP) is a pre-clinical stage product being developed by Rockwell Medical for End Stage Renal Disease (ESRD). The current trial status is terminated. This product is registered under clinical trial identifier NCT00604565. Target conditions include End Stage Renal Disease (ESRD).
What happened to similar drugs?
20 of 20 similar drugs in End Stage Renal Disease (ESRD) were approved
Approved (20) Terminated (2) Active (0)
✅Henagliflozin 5 mg Group + Henagliflozin 10 mg Group + Conventional therapy groupJiangsu Hengrui MedicineApproved
Hype Score Breakdown
Clinical
3
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01322347 | Phase 3 | Completed |
| NCT01320202 | Phase 3 | Completed |
| NCT00604565 | Pre-clinical | Terminated |
Competing Products
20 competing products in End Stage Renal Disease (ESRD)